Opinion|Videos|January 20, 2025

Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.


Latest CME